Sandoz Group AG
Avatud
67.34 0.36
Ülevaade
Aktsiahinna muutus
24h
Min
67.02
Max
67.9
Sissetulek | 160M 537M |
|---|---|
Müük | 641M 5.9B |
P/E Sektori keskmine | 38.795 49.052 |
Aktsiakasum | 1.238 |
Dividenditootlus | 1.59 |
Kasumimarginaal | 9.093 |
Töötajad | 22,356 |
EBITDA | 427M 1B |
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | +10.39% upside |
Dividenditootlus Sektori keskmine | 1.59% 2.36% |
|---|---|
Järgmine tulemuste avaldamine | 5. aug 2026 |
Turukapital | -1.1B 28B |
|---|---|
Eelmine avamishind | 66.98 |
Eelmine sulgemishind | 67.34 |
Sandoz Group AG Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Ettevõttest Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.
